Scarica l'app Stockscreener
103.36
1.78%
-1.87
Dopo l'orario di chiusura:
103.00
-0.36
-0.35%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Abbott Laboratories Borsa (ABT) Ultime notizie
Top Research Reports for Goldman Sachs, RTX & Abbott - Yahoo Finance
Abbott Laboratories Share Price Today (ABT) | Live Chart, News & Stock Market - TechGraph
Abbott Spinal Cord Stimulator Explant Surgery Required After Device Failure: Lawsuit - AboutLawsuits.com
Abbott Laboratories stock falls after FDA approval - ad-hoc-news.de
Abbott Laboratories stock before the bell falls 2.6 percent - ad-hoc-news.de
Abbott Laboratories (ABT) Secured FDA Approval, Is It Still 11% Below Fair Value? - simplywall.st
Abbott Wins FDA Clearance for Dual-Energy AFib Catheter - finance.biggo.com
Abbott partners with Sengkang General Hospital to advance early detection of muscle loss in Singapore - BioSpectrum Asia
Abbott Is Selling Sterility as a Feature. In Liquid Formula It Is Already the Rule. - marlerblog.com
Abbott Receives FDA Nod for TactiFlex Duo: Stock to Gain? - Yahoo Finance
Abbott garners FDA nod for its TactiFlex catheter to treat AFib - Fierce Biotech
Abbott’s dual ablation catheter lands FDA approval - Yahoo Finance
Abbott Laboratories stock gains after FDA approval and strong guidance - ad-hoc-news.de
Abbott Laboratories stock heads into the open after a modest loss - ad-hoc-news.de
Here's Why Abbott (ABT) Fell More Than Broader Market - Yahoo Finance
Abbott Laboratories stock underperforms Tuesday when compared to competitors - MarketWatch
1 No-Brainer ETF I'm Loading Up on in 2026 and Beyond - The Motley Fool
FDA approves new Abbott catheter capable of PFA and radiofrequency ablation - Cardiovascular Business
Abbott wins FDA approval for dual-energy ablation catheter - MedTech Dive
Abbott receives FDA approval for AFib ablation catheter - grafa.com
Abbott Laboratories (ABT) Won FDA Approval For Its TactiFlex Duo Catheter - simplywall.st
Abbott scores another win at UPC with SiBio preliminary injunction - IAM Patent
Abbott receives FDA approval for dual-energy heart ablation catheter By Investing.com - Investing.com Canada
Abbott wins FDA nod for cardiac ablation catheter (ABT:NYSE) - Seeking Alpha
The FDA Clears an Abbott Product - marketscreener.com
Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms - PR Newswire
Abbott Laboratories stock holds firm after July earnings - AD HOC NEWS
Abbott Laboratories (NYSE:ABT): Can Heart Research Lift Its Next Move? - Kalkine Media
Abbott Blocks Rival's Glucose Monitor Sales In Europe - Law360
Abbott Laboratories stock holds valuation premium amid steady earnings - ad-hoc-news.de
Abbott Laboratories (ABT) Stock Analysis: Analyst Consensus Reveals a 10.96% Upside Potential - DirectorsTalk Interviews
Abbott Stock And Other Defensive Dividend Picks For Uncertain Markets - simplywall.st
Abbott Laboratories stock holds near $108 after strong Q2 - AD HOC NEWS
Abbott Laboratories Profile: Recipients - OpenSecrets
Abbott Laboratories (ABT) Q2 2026 Earnings Call Transcript - Fortune
How New Diabetes, Cardiac, Nutrition and Cancer Tools At Abbott Laboratories (ABT) Have Changed Its Investment Story - simplywall.st
Abbott CFO Philip P. Boudreau Retains 70,784 Shares After Forfeiting 388 Shares at $110.36 Each - Kalkine Media
Ferguson Wellman Capital Management Inc. Sells 136,385 Shares of Abbott Laboratories $ABT - InsuranceNewsNet
Renal Denervation Market Size, Share & Trends Analysis - GlobeNewswire Inc.
US companies face rise in cyber attacks - Reuters
Abbott Laboratories CFO Philip P. Boudreau Reports Sale of 388 Shares at $110.36 in SEC Form 4 Filing - Kalkine Media
Abbott Laboratories VP John A. McCoy Jr. Reports Share Sales on September 1-2, 2026 - Kalkine Media
Abbott Laboratories (ABT) CFO reports small tax-related share disposal - Stock Titan
Abbott Laboratories stock underperforms Thursday when compared to competitors - MarketWatch
Abbott Laboratories stock gains support from fresh earnings and guidance - AD HOC NEWS
Abbott ablation device effective at 1 year in complex cases - MedTech Dive
Small Abbott (NYSE: ABT) insider sale from vested stock award - Stock Titan
Abbott Laboratories stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Abbott settlement and Kendamil case add to formula industry scrutiny - FoodNavigator.com
J.P. Morgan Maintains Abbott Laboratories(ABT.US) With Buy Rating - Moomoo
Abbott Introduces America’s First Liquid Baby Formula With Whole Milk - Yahoo Finance
Abbott Laboratories Stock: Is ABT Underperforming the Healthcare Sector? - Barchart.com
Abbott Laboratories stock underperforms Monday when compared to competitors - MarketWatch
How Abbott Labs Is Embracing RFK Jr.'s Make America Healthy Again Movement - Investor's Business Daily
Two Recessions Couldn’t Stop These 4 Healthcare Stocks From Raising Dividends - 24/7 Wall St.
Abbott Laboratories Introduces Similac 360 Total Care Made With Whole Milk in US - marketscreener.com
No mixing: Similac's whole-milk formula launches at powder-like prices - Stock Titan
Abbott Laboratories (ABT) Stock Analysis: A Healthy Outlook With A 6.87% Upside - DirectorsTalk Interviews
TD Cowen Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $135 - Moomoo
Abbott Laboratories (ABT) Could Be 6% Below Fair Value Following Libre Duo FDA Approval - simplywall.st
Abbott wins CE mark for new LAA closure device - medtechdive.com
Abbott Laboratories agrees to $670M settlement over premature infant formula claims - Top Class Actions
0.29%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):